Glenmark Pharmaceuticals ltd — Capital/Financing Update 2018

Aug 29, 2018

==> picture [33 x 32] intentionally omitted <==

==> picture [148 x 45] intentionally omitted <==

August 29, 2018

To, To, Dy. General Manager The Manager – Listing, Department of Corporate Services, The National Stock Exchange of India Ltd., BSE Ltd., Plot No. C/1, G Block, P. J. Towers, Dalal Street, Bandra Kurla Complex, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051

Ref: Scrip Code: 532296 Ref: Scrip Name: GLENMARK

Dear Sirs,

Sub: Glenmark enters into an exclusive licensing agreement to commercialize generic Tiotropium Bromide dry powder inhaler in Western Europe

With reference to the above subject mentioned above, kindly find attached media release which is selfexplanatory.

Requesting you to kindly take the same on record.

Thanking You.

Yours faithfully,

For Glenmark Pharmaceuticals Limited

Digitally signed by HARISH HARISH VINAYAK KUBER VINAYAK KUBER Date: 2018.08.29 08:38:14 +05'30' Harish Kuber Company Secretary & Compliance Officer

==> picture [596 x 76] intentionally omitted <==

Press Release For Immediate Release

Glenmark enters into an exclusive licensing agreement to commercialize generic Tiotropium Bromide dry powder inhaler in Western Europe

• Tiotropium Bromide DPI, a generic version of Boehringer Ingelheim’s Spiriva® Handihaler, is used in the treatment of chronic obstructive pulmonary disease (COPD)

• This is the second inhalation product in-licensed by Glenmark for the European market after Fluticasone/Salmeterol dry powder inhaler

Mumbai, August 29, 2018: Glenmark Pharmaceuticals Ltd, a research-led global integrated pharmaceutical company, announced today that Glenmark Pharmaceuticals Europe has entered into a strategic, exclusive licensing agreement for marketing generic Tiotropium Bromide dry powder inhaler (DPI) in Western Europe.

Tiotropium Bromide DPI is a generic version of Boehringer Ingelheim’s Spiriva® Handihaler. The product is used in the treatment of chronic obstructive pulmonary disease (COPD).

This is the second inhalation product in-licensed by Glenmark for the European market after Fluticasone/Salmeterol dry powder inhaler.

“Respiratory is a core area of focus for Glenmark and this deal shows our commitment to increase product offerings within this segment. There is significant opportunity in the inhalers market and we believe that this deal will give further impetus to Glenmark’s growth in Europe,” said Achin Gupta, EVP & Business Head of Europe and Latin America, Glenmark Pharmaceuticals Ltd.

According to data from IQVIA, Boehringer Ingelheim’s Spiriva® Handihaler recorded sales of USD 724 million in the EU in the 12 month period ended March 2018.

--End--

About Glenmark Pharmaceuticals Ltd:

Glenmark Pharmaceuticals Ltd. (GPL) is a research-driven, global, integrated pharmaceutical organization. It is ranked among the top 75 Pharma & Biotech companies of the world in terms of revenue (SCRIP 100 Rankings published in the year 2017). Glenmark is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity). Glenmark has several molecules in various stages of clinical development and is focused in the areas of oncology, dermatology and respiratory.

==> picture [596 x 76] intentionally omitted <==

The company has a significant presence in the branded generics markets across emerging economies including India. Glenmark has 16 manufacturing facilities across five countries and has six R&D centers. The Generics business of Glenmark services the requirements of the US and Western European markets. The API business sells its products in over 80 countries, including the US, various countries in the EU, South America and India.

For more information, please contact:

Isha Trivedi Glenmark, Mumbai, India

Tel: +91 22 4018 9801 Email: corpcomm@glenmarkpharma.com